Intersect ENT Stock Price, News & Analysis (NASDAQ:XENT)

$28.55 -0.35 (-1.21 %)
(As of 11/18/2017 09:33 AM ET)
Previous Close$28.55
Today's Range$28.38 - $29.05
52-Week Range$9.20 - $33.25
Volume149,699 shs
Average Volume238,708 shs
Market Capitalization$840.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.68

About Intersect ENT (NASDAQ:XENT)

Intersect ENT logoIntersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.


Industry, Sector and Symbol:
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:XENT
  • CUSIP: N/A
  • Web: www.intersectent.com
Debt:
  • Current Ratio: 8.47%
  • Quick Ratio: 7.87%
Sales & Book Value:
  • Annual Sales: $78.71 million
  • Price / Sales: 10.69
  • Book Value: $3.87 per share
  • Price / Book: 7.38
Profitability:
  • Trailing EPS: ($0.63)
  • Net Income: ($25,220,000.00)
  • Net Margins: -19.81%
  • Return on Equity: -15.96%
  • Return on Assets: -14.16%
Misc:
  • Employees: 303
  • Outstanding Shares: 29,460,000
 

Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its earnings results on Thursday, November, 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05. The medical equipment provider earned $22.31 million during the quarter, compared to analyst estimates of $21.53 million. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. Intersect ENT's revenue was up 20.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.22) EPS. View Intersect ENT's Earnings History.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

9 analysts have issued twelve-month price objectives for Intersect ENT's stock. Their forecasts range from $20.00 to $40.00. On average, they expect Intersect ENT's share price to reach $30.57 in the next twelve months. View Analyst Ratings for Intersect ENT.

What are Wall Street analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

  • 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (11/1/2017)
  • 2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Who are some of Intersect ENT's key competitors?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:

  • Lisa D. Earnhardt, President, Chief Executive Officer, Director (Age 47)
  • Jeryl L. Hilleman, Chief Financial Officer (Age 59)
  • Richard E. Kaufman, Senior Vice President, Chief Operating Officer (Age 55)
  • David A. Lehman, General Counsel (Age 56)
  • Gwen Carscadden, Chief People Officer (Age 55)
  • Kieran T. Gallahue, Lead Director (Age 53)
  • Teresa L. Kline, Director
  • William Anthony Vernon, Director (Age 61)
  • Cynthia L. Lucchese, Independent Director (Age 56)
  • Dana G. Mead Jr., Independent Director (Age 57)

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (5.70%), Neuberger Berman Group LLC (2.72%), Pura Vida Investments LLC (0.68%), Bank of New York Mellon Corp (0.62%), EAM Investors LLC (0.56%) and Schwab Charles Investment Management Inc. (0.39%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Formula Growth Ltd., Mutual of America Capital Management LLC, Boston Advisors LLC, Ameriprise Financial Inc., California State Teachers Retirement System, Bank of New York Mellon Corp and Strs Ohio. Company insiders that have sold Intersect ENT company stock in the last year include Frederic H Moll, Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

Who bought Intersect ENT stock? Who is buying Intersect ENT stock?

Intersect ENT's stock was bought by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP, Neuberger Berman Group LLC, Chicago Equity Partners LLC, Mackenzie Financial Corp, Schwab Charles Investment Management Inc., Iguana Healthcare Management LLC, USA Financial Portformulas Corp and California Public Employees Retirement System. View Insider Buying and Selling for Intersect ENT.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of Intersect ENT stock can currently be purchased for approximately $28.55.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $840.97 million and generates $78.71 million in revenue each year. The medical equipment provider earns ($25,220,000.00) in net income (profit) each year or ($0.63) on an earnings per share basis. Intersect ENT employs 303 workers across the globe.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]


MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Intersect ENT (NASDAQ:XENT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 7 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $30.57 (7.08% upside)

Consensus Price Target History for Intersect ENT (NASDAQ:XENT)

Price Target History for Intersect ENT (NASDAQ:XENT)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/7/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
11/3/2017Northland SecuritiesReiterated RatingHold$25.00N/AView Rating Details
9/13/2017Canaccord GenuityBoost Price TargetBuy$32.00 -> $37.00LowView Rating Details
9/11/2017Bank of America CorporationBoost Price TargetBuy$33.00 -> $40.00HighView Rating Details
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00LowView Rating Details
8/2/2017Deutsche Bank AGSet Price TargetBuy$27.00 -> $31.00HighView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
5/3/2017WedbushBoost Price TargetOutperform -> Outperform$25.00 -> $26.00HighView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$20.00N/AView Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $14.00N/AView Rating Details
11/2/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$25.00 -> $16.00N/AView Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Intersect ENT (NASDAQ:XENT)

Earnings by Quarter for Intersect ENT (NASDAQ:XENT)

Earnings History by Quarter for Intersect ENT (NASDAQ XENT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.20)($0.15)$21.53 million$22.31 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.19)($0.08)$22.62 million$24.00 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.25)($0.23)$19.39 million$20.47 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.17)$23.47 million$24.20 millionViewListenView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intersect ENT (NASDAQ:XENT)
2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.22)($0.24)
Q2 20173($0.19)($0.19)($0.19)
Q3 20173($0.26)($0.17)($0.21)
Q4 20173($0.17)($0.06)($0.13)
Q1 20182($0.16)($0.08)($0.12)
Q2 20182($0.12)($0.11)($0.12)
Q3 20182($0.14)($0.11)($0.13)
Q4 20182($0.14)($0.06)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ XENT)

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 80.23%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Insider Trades by Quarter for Intersect ENT (NASDAQ XENT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Frederic H MollDirectorSell800$29.00$23,200.00View SEC Filing  
11/6/2017Jeryl L HillemanCFOSell12,833$27.78$356,500.74View SEC Filing  
10/16/2017Lisa D EarnhardtInsiderSell20,000$28.37$567,400.00View SEC Filing  
10/4/2017Jeryl L HillemanCFOSell12,833$29.96$384,476.68View SEC Filing  
9/25/2017Richard E KaufmanCOOSell13,639$28.97$395,121.83View SEC Filing  
9/15/2017Lisa D EarnhardtInsiderSell20,000$30.19$603,800.00View SEC Filing  
9/5/2017Jeryl L HillemanCFOSell12,833$31.05$398,464.65View SEC Filing  
8/28/2017Richard E KaufmanCOOSell22,425$30.22$677,683.50View SEC Filing  
8/15/2017Lisa D EarnhardtInsiderSell20,000$30.79$615,800.00View SEC Filing  
8/4/2017Jeryl L HillemanCFOSell12,833$29.00$372,157.00View SEC Filing  
7/25/2017Richard E KaufmanCOOSell12,500$28.25$353,125.00View SEC Filing  
7/17/2017Lisa D EarnhardtInsiderSell20,000$29.03$580,600.00View SEC Filing  
7/10/2017Jeryl L HillemanCFOSell12,835$27.18$348,855.30View SEC Filing  
6/15/2017Lisa D EarnhardtInsiderSell20,000$26.10$522,000.00View SEC Filing  
5/22/2017Richard E KaufmanCOOSell20,000$22.87$457,400.00View SEC Filing  
5/15/2017Lisa D EarnhardtInsiderSell20,000$22.98$459,600.00View SEC Filing  
4/20/2017Richard E KaufmanCOOSell1,250$17.25$21,562.50View SEC Filing  
4/17/2017Lisa D EarnhardtInsiderSell20,000$16.06$321,200.00View SEC Filing  
3/15/2017Lisa D EarnhardtInsiderSell20,000$15.02$300,400.00View SEC Filing  
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.12View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.00View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.00View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Intersect ENT (NASDAQ XENT)

Source:
DateHeadline
Intersect ENT, Inc. (XENT) Director Sells $23,200.00 in StockIntersect ENT, Inc. (XENT) Director Sells $23,200.00 in Stock
www.americanbankingnews.com - November 14 at 9:50 PM
$27.68 Million in Sales Expected for Intersect ENT, Inc. (XENT) This Quarter$27.68 Million in Sales Expected for Intersect ENT, Inc. (XENT) This Quarter
www.americanbankingnews.com - November 11 at 2:54 AM
FDA Performs Pre-Approval Inspection Of Intersect ENTs Menlo Park FacilityFDA Performs Pre-Approval Inspection Of Intersect ENT's Menlo Park Facility
www.thestreet.com - November 8 at 12:16 AM
Intersect ENT, Inc. (XENT) CFO Sells $356,500.74 in StockIntersect ENT, Inc. (XENT) CFO Sells $356,500.74 in Stock
www.americanbankingnews.com - November 6 at 9:21 PM
Intersect ENT (XENT) Says FDA Performed Pre-Approval Inspection of its Menlo Park Facility - StreetInsider.comIntersect ENT (XENT) Says FDA Performed Pre-Approval Inspection of its Menlo Park Facility - StreetInsider.com
www.streetinsider.com - November 6 at 9:39 AM
FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park FacilityFDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park Facility
finance.yahoo.com - November 6 at 9:39 AM
Edited Transcript of XENT earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of XENT earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 5 at 8:23 AM
Edited Transcript of XENT earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of XENT earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 5 at 8:23 AM
Intersect ENT, Inc. (XENT) Announces Quarterly  Earnings Results, Beats Expectations By $0.05 EPSIntersect ENT, Inc. (XENT) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - November 3 at 3:22 PM
Intersect ENTs (XENT) Hold Rating Reiterated at Northland SecuritiesIntersect ENT's (XENT) Hold Rating Reiterated at Northland Securities
www.americanbankingnews.com - November 3 at 11:24 AM
Intersect ENT Inc to Host Earnings CallIntersect ENT Inc to Host Earnings Call
finance.yahoo.com - November 2 at 11:48 AM
Intersect ENT Inc to Host Earnings CallIntersect ENT Inc to Host Earnings Call
finance.yahoo.com - November 2 at 11:48 AM
Intersect ENT, Inc. (XENT) Rating Lowered to Hold at Zacks Investment ResearchIntersect ENT, Inc. (XENT) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 1 at 2:23 PM
Financial Survey: Intersect ENT (XENT) vs. Exactech (EXAC)Financial Survey: Intersect ENT (XENT) vs. Exactech (EXAC)
www.americanbankingnews.com - November 1 at 1:08 PM
Intersect ENT, Inc. (XENT) Receives Average Rating of "Buy" from AnalystsIntersect ENT, Inc. (XENT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 1 at 1:52 AM
Critical Contrast: Intersect ENT (XENT) & The CompetitionCritical Contrast: Intersect ENT (XENT) & The Competition
www.americanbankingnews.com - October 28 at 1:28 PM
Contrasting Intersect ENT (XENT) and Its CompetitorsContrasting Intersect ENT (XENT) and Its Competitors
www.americanbankingnews.com - October 25 at 10:44 AM
Intersect ENT, Inc. (XENT) Scheduled to Post Earnings on TuesdayIntersect ENT, Inc. (XENT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 24 at 8:56 AM
Intersect ENT, Inc. (XENT) Expected to Announce Quarterly Sales of $21.52 MillionIntersect ENT, Inc. (XENT) Expected to Announce Quarterly Sales of $21.52 Million
www.americanbankingnews.com - October 23 at 1:40 PM
Intersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : October 23, 2017Intersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : October 23, 2017
finance.yahoo.com - October 23 at 9:16 AM
 Brokerages Anticipate Intersect ENT, Inc. (XENT) to Post -$0.20 EPS Brokerages Anticipate Intersect ENT, Inc. (XENT) to Post -$0.20 EPS
www.americanbankingnews.com - October 21 at 2:22 AM
Intersect ENT, Inc. (XENT) Forecasted to Earn Q1 2018 Earnings of ($0.08) Per ShareIntersect ENT, Inc. (XENT) Forecasted to Earn Q1 2018 Earnings of ($0.08) Per Share
www.americanbankingnews.com - October 18 at 11:28 AM
Commit To Buy Intersect ENT At $25, Earn 16.6% Annualized Using OptionsCommit To Buy Intersect ENT At $25, Earn 16.6% Annualized Using Options
www.nasdaq.com - October 18 at 10:52 AM
Intersect ENT, Inc. (XENT) Insider Lisa D. Earnhardt Sells 20,000 SharesIntersect ENT, Inc. (XENT) Insider Lisa D. Earnhardt Sells 20,000 Shares
www.americanbankingnews.com - October 17 at 7:26 PM
Intersect ENT, Inc. Forecasted to Earn Q2 2018 Earnings of ($0.11) Per Share (XENT)Intersect ENT, Inc. Forecasted to Earn Q2 2018 Earnings of ($0.11) Per Share (XENT)
www.americanbankingnews.com - October 17 at 11:46 AM
Intersect ENT to Report Third Quarter 2017 Financial ResultsIntersect ENT to Report Third Quarter 2017 Financial Results
finance.yahoo.com - October 17 at 9:24 AM
Ocular Therapeutix (OCUL) vs. Intersect ENT (XENT) Head-To-Head ComparisonOcular Therapeutix (OCUL) vs. Intersect ENT (XENT) Head-To-Head Comparison
www.americanbankingnews.com - October 14 at 12:36 PM
ETFs with exposure to Intersect ENT, Inc. : October 10, 2017ETFs with exposure to Intersect ENT, Inc. : October 10, 2017
finance.yahoo.com - October 11 at 9:43 AM
ETFs with exposure to Intersect ENT, Inc. : October 10, 2017ETFs with exposure to Intersect ENT, Inc. : October 10, 2017
finance.yahoo.com - October 11 at 9:43 AM
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENTThe Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT
finance.yahoo.com - October 11 at 9:43 AM
Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
finance.yahoo.com - October 10 at 8:31 AM
INTERSECT ENT INCINTERSECT ENT INC
www.finanznachrichten.de - October 9 at 9:32 AM
Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus ImplantIntersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant
finance.yahoo.com - October 9 at 9:32 AM
Intersect ENT (XENT) and Its Competitors Financial AnalysisIntersect ENT (XENT) and Its Competitors Financial Analysis
www.americanbankingnews.com - October 6 at 4:10 PM
Insider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of StockInsider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock
www.americanbankingnews.com - October 5 at 7:26 PM
The Saga to Revoke Obamacare Continues: 3 MedTech Picks - NasdaqThe Saga to Revoke Obamacare Continues: 3 MedTech Picks - Nasdaq
www.nasdaq.com - October 5 at 6:34 PM
The Saga to Revoke Obamacare Continues: 3 MedTech PicksThe Saga to Revoke Obamacare Continues: 3 MedTech Picks
finance.yahoo.com - October 5 at 6:34 PM
Intersect ENT, Inc. (XENT) Stock Rating Upgraded by Zacks Investment ResearchIntersect ENT, Inc. (XENT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 5 at 9:50 AM
Intersect ENT, Inc. (XENT) Expected to Announce Earnings of -$0.20 Per ShareIntersect ENT, Inc. (XENT) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - October 2 at 8:32 AM
Insider Selling: Intersect ENT, Inc. (XENT) COO Sells 13,639 Shares of StockInsider Selling: Intersect ENT, Inc. (XENT) COO Sells 13,639 Shares of Stock
www.americanbankingnews.com - September 27 at 7:46 PM
Intersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : September 21, 2017Intersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : September 21, 2017
finance.yahoo.com - September 23 at 12:13 PM
Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : September 22, 2017Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : September 22, 2017
finance.yahoo.com - September 23 at 12:13 PM
Canaccord Genuity Reiterates "Buy" Rating for Intersect ENT, Inc. (XENT)Canaccord Genuity Reiterates "Buy" Rating for Intersect ENT, Inc. (XENT)
www.americanbankingnews.com - September 13 at 3:34 PM
Analysts Issue Forecasts for Intersect ENT, Inc.s Q3 2017 Earnings (XENT)Analysts Issue Forecasts for Intersect ENT, Inc.'s Q3 2017 Earnings (XENT)
www.americanbankingnews.com - September 13 at 7:42 AM
Intersect ENT (XENT) Reports Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety ... - StreetInsider.comIntersect ENT (XENT) Reports Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety ... - StreetInsider.com
www.streetinsider.com - September 12 at 12:30 PM
Intersect ENT, Inc. (XENT) Receives Average Recommendation of "Buy" from AnalystsIntersect ENT, Inc. (XENT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 12 at 3:06 AM
Intersect ENT, Inc. (XENT) Price Target Increased to $40.00 by Analysts at Bank of America CorporationIntersect ENT, Inc. (XENT) Price Target Increased to $40.00 by Analysts at Bank of America Corporation
www.americanbankingnews.com - September 11 at 8:22 AM
Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and ... - Business Wire (press release)Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and ... - Business Wire (press release)
www.businesswire.com - September 10 at 9:59 AM
Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus ImplantIntersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant
finance.yahoo.com - September 10 at 9:59 AM
Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT, Inc. (XENT) StockJeryl L. Hilleman Sells 12,833 Shares of Intersect ENT, Inc. (XENT) Stock
www.americanbankingnews.com - September 6 at 8:26 PM

Social Media

Financials

Chart

Intersect ENT (NASDAQ XENT) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.